TY - JOUR T1 - Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression JF - Life Science Alliance JO - Life Sci. Alliance DO - 10.26508/lsa.202000955 VL - 4 IS - 2 SP - e202000955 AU - André F Rendeiro AU - Joseph Casano AU - Charles Kyriakos Vorkas AU - Harjot Singh AU - Ayana Morales AU - Robert A DeSimone AU - Grant B Ellsworth AU - Rosemary Soave AU - Shashi N Kapadia AU - Kohta Saito AU - Christopher D Brown AU - JingMei Hsu AU - Christopher Kyriakides AU - Steven Chiu AU - Luca Vincenzo Cappelli AU - Maria Teresa Cacciapuoti AU - Wayne Tam AU - Lorenzo Galluzzi AU - Paul D Simonson AU - Olivier Elemento AU - Mirella Salvatore AU - Giorgio Inghirami Y1 - 2021/02/01 UR - https://www.life-science-alliance.org/content/4/2/e202000955.abstract N2 - With a rising incidence of COVID-19–associated morbidity and mortality worldwide, it is critical to elucidate the innate and adaptive immune responses that drive disease severity. We performed longitudinal immune profiling of peripheral blood mononuclear cells from 45 patients and healthy donors. We observed a dynamic immune landscape of innate and adaptive immune cells in disease progression and absolute changes of lymphocyte and myeloid cells in severe versus mild cases or healthy controls. Intubation and death were coupled with selected natural killer cell KIR receptor usage and IgM+ B cells and associated with profound CD4 and CD8 T-cell exhaustion. Pseudo-temporal reconstruction of the hierarchy of disease progression revealed dynamic time changes in the global population recapitulating individual patients and the development of an eight-marker classifier of disease severity. Estimating the effect of clinical progression on the immune response and early assessment of disease progression risks may allow implementation of tailored therapies. ER -